Vontobel Holding Ltd. Cellectis S.A. Transaction History

Vontobel Holding Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 03, 2024	BUY	$1.83 - $3.84 $54,900 - $115,200	30,000 New	30,000 $57,000
Q1 2023 Apr 12, 2023	BUY	$1.83 - $3.84 $29,280 - $61,440	16,000 Added 114.29%	30,000 $57,000
Q4 2021 Feb 14, 2022	SELL	$8.01 - $12.84 $666,536 - $1.07 Million	-83,213 Reduced 85.6%	14,000 $114,000
Q3 2021 Oct 29, 2021	SELL	$11.94 - $16.09 $24,859 - $33,499	-2,082 Reduced 2.1%	97,213 $1.23 Million
Q2 2021 Aug 06, 2021	BUY	$14.36 - $20.93 $173,454 - $252,813	12,079 Added 13.85%	99,295 $1.54 Million

Q1 2021 May 11, 2021	BUY	$18.19 - $33.25 $7,567 - $13,832	416 Added 0.48%	87,216 $1.76 Million
Q4 2020 Feb 12, 2021	BUY	$15.87 - $31.64 $1.38 Million - $2.75 Million	86,800 New	86,800 $2.35 Million

9.83M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.7M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.